MINNEAPOLIS, MN, May 14, 2013 /PRNewswire/ - BioAmber Inc. ("BioAmber")
(NYSE: BIOA.U), announced today the closing of its initial public
offering of 8,000,000 units consisting of one share of common stock and
one warrant to purchase half of one share of common stock at $10.00 per
unit, before underwriting discounts and commissions. Each warrant will
be exercisable at an exercise price of $11.00 per whole share of common
stock. All units are being sold by BioAmber. The units are listed on
the New York Stock Exchange ("NYSE") under the symbol "BIOA.U". The
common stock and warrants comprising the units will begin trading
separately on NYSE under the symbols "BIOA" and "BIOA.WS",
respectively, on Monday, June 10, 2013 at which time trading of the
units will be suspended and the units will be delisted. BioAmber also
intends to list its common stock on the Professional Segment of the
regulated market of NYSE Euronext in Paris under the symbol "BIOA."
Credit Suisse, Barclays and Société Générale are acting as joint
book-running managers for the offering. Pacific Crest Securities is
acting as co-manager for the offering.
A registration statement relating to these securities has been filed
with, and declared effective by, the U.S. Securities and Exchange
Commission on May 9, 2013. This press release shall not constitute an
offer to sell or the solicitation of an offer to buy, nor shall there
be any sale of these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
The offering of these securities was made only by means of a prospectus,
copies of which may be obtained from Credit Suisse Securities (USA)
LLC by mail at One Madison Avenue, New York, New York 10010,
Attention: Prospectus Department, or by calling toll free (800)
221-1037, or by emailing newyork.prospectus@credit-suisse.com.
About BioAmber Inc.
BioAmber is a next generation chemicals company. Its proprietary
technology platform combines industrial biotechnology and chemical
catalysis to convert renewable feedstocks into chemicals including
succinic acid and 1,4-butanediol, which are used in a wide variety of
everyday products such as plastics, food additives and personal care
products. For more information visit the company's web site at: www.bio-amber.com.
Forward-Looking Statements
This press release contains forward-looking statements, which are
subject to substantial risks, uncertainties and assumptions. These
statements often include words such as "believe," "expect,"
"anticipate," "intend," "plan," "estimate," "seek," "will," "may" or
similar expressions. Although we believe that the expectations
reflected in the forward-looking statements are reasonable, we cannot
guarantee that the events and circumstances reflected in the
forward-looking statements will be achieved or occur and the timing of
events and circumstances and actual results could differ materially
from those projected in the forward- looking statements. Accordingly,
you should not place undue reliance on these forward-looking
statements. All such statements speak only as of the date made, and we
undertake no obligation to update or revise publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise.
SOURCE BIOAMBER CANADA INC.